Abstracts tagged "morbidity and mortality and rheumatic disease"

Abstract Number: 1972 • 2017 ACR/ARHP Annual Meeting
Causes of Death in 350 Patients with Systemic Autoimmune Rheumatic Diseases
Juan Gabriel Ovalles-Bonilla^1,2, Olaia Fernández-Berrizbeitia³, Julia Martínez-Barrio¹, Larissa Valor¹, Diana Hernández¹, Iustina Janta¹, Belen Serrano¹, Claudia Saez¹, Roberto Gonzalez¹, María Correyero¹, Leticia García¹, Ana López-Cerón¹, Alicia Silva¹, Juan Carlos Nieto¹, Carlos González^1,4, Indalecio Monteagudo¹ and Francisco Javier López Longo^1,4, ¹Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, ³Rheumatology, Hospital Universitario Basurto, Bilbao, Spain, ⁴Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
Background/Purpose: The major SARD have an increased mortality compared to the general population. It is well known that the main causes of death in Systemic…
Abstract Number: 2168 • 2016 ACR/ARHP Annual Meeting
Metabolic Syndrome, All Cause Mortality and Atherosclerotic Cardiovascular Disease in Rheumatic Diseases
Marco Antivalle^1,2, Valentina Varisco², Alessandra Mutti², Alberto Batticciotto², Maria Chiara Ditto², Fabiola Atzeni³ and Piercarlo Sarzi-Puttini², ¹Rheumatology, Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy, ²Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milan, Italy, ³Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy
Background/Purpose: all-cause and cardiovascular mortality and cardiovascular morbidity are reportedly increased in rheumatic diseases, both inflammatory and non-inflammatory. Few studies, however have addressed the impact…
Abstract Number: 43 • 2015 ACR/ARHP Annual Meeting
Prevalence and Relevance of Depressive Symptoms in Patients with Rheumatic Diseases
Stefan Kleinert^1,2, Almuth Marx³, Hermann Faller⁴, Martin Feuchtenberger⁵, Christian Kneitz⁶, Stefanie Lehmann³, Hans Peter Tony⁷, Christiane Angermann^3,8, Georg Ertl⁸, Stefan Störk³ and Margret Breunig^3,9, ¹Rheumatologische Schwerpunktpraxis Erlangen, Erlangen, Germany, ²University Hospital Würzburg, Würzburg, Germany, ³Comprehensive Heart Failure Center, University of Würzburg, Würzburg, Germany, ⁴Abteilung für Medizinische Psychologie und Psychotherapie, University of Würzburg, Würzburg, Germany, ⁵Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, ⁶Internal Medicine II, Hospital Südstadt, Rostock, Germany, ⁷Rheumatology / Clinical Immunology, University Hospital Würzburg, Würzburg, Germany, ⁸Dept. of Internal Medicine / Cardiology, University Hospital Würzburg, Würzburg, Germany, ⁹Dept. of Internal Medicine / Cardiology, University Hospital Würzburg, Würzburg, Wuerzburg, Germany
Background/Purpose: Patients with rheumatic diseases (RD) have an increased mortality risk compared to the normal population. The current prospective follow-up study investigated the prevalence of…
Abstract Number: 1756 • 2013 ACR/ARHP Annual Meeting
Trends In Incidence and Mortality In Rheumatoid Arthritis and Systemic Autoimmune Rheumatic Diseases In Quebec, Canada: A Population-Based Study
Sonia Jean¹, Philippe Gamache², Marie Hudson³, Louis Bessette⁴, Paul R. Fortin⁵, Gilles Boire⁶ and Sasha Bernatsky⁷, ¹Chronic disease surveillence division, National Institute of public health of Quebec, Quebec, QC, Canada, ²Chronic disease surveillance division, National institute of public health of Quebec, Quebec, QC, Canada, ³Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ⁴Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, Canada, ⁵Medicine, Centre de Recherche du Chu de Québec et Université Laval, Quebec City, QC, Canada, ⁶Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁷Clinical Epidemiology, Research Institute of the McGill University Health Ctre, Montreal, QC, Canada
Background/Purpose: Health administrative data (HAD) are a potentially efficient to conduct population-based research and are increasingly used to develop chronic disease surveillance indicators. Examining trends…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].